A proposed mechanism for chemotherapy-related cognitive impairment ('chemo-fog')

Journal of Clinical Pharmacy and Therapeutics

Volumn 36, Issue 3, 2011, Pages 257-259

  Raffa, R B ^a  

^a TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN;

CANCER CHEMOTHERAPY; CANCER SURVIVOR; COGNITIVE DEFECT; HUMAN; MILD COGNITIVE IMPAIRMENT; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; COGNITION DISORDERS; CYTOKINES; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEURONS; SURVIVORS;

EID: 79955777701     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2010.01188.x     Document Type: Review

References (12)

1. Raffa RB, Duong PV, Finney J, et al. (2006) Is 'chemo-fog'/'chemo-brain' caused by cancer chemotherapy? Journal of Clinical Pharmacy and Therapeutics, 31, 129-138.
2. Raffa RB, Tallarida RJ, eds (2010) Chemofog: cancer chemotherapy-related cognitive impairment. Austin: Springer/Landes.
3. Raffa RB, (2010) Is a picture worth a thousand (forgotten) words?: neuroimaging evidence for the cognitive deficits in 'chemo-fog'/'chemo-brain'. Journal of Clinical Pharmacy and Therapeutics, 35, 1-9.
4. Foley JJ, Raffa RB, Walker EA, (2008) Effects of chemotherapeutic agents 5-fluorouracil and methotrexate alone and combined in a mouse model of learning and memory. Psychopharmacology, 199, 527-538.
5. Silberfarb PM, Philibert D, Levine PM, (1980) Psychosocial aspects of neoplastic disease: II. Affective and cognitive effects of chemotherapy in cancer patients. American Journal of Psychiatry, 137, 597-601. (Pubitemid 10107447)
6. van Dam FS, Schagen SB, Muller MJ, et al. (1998) Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. Journal of the National Cancer Institute, 90, 210-218. (Pubitemid 28114539)
7. Aluise CD, Sultana R, Tangpong J, et al. (2010) Chemobrain (chemofog) as a potential side effect of doxorubicin administration: role of cytokine-induced, oxidative/nitrosative stress in cognitive dysfunction. In:, Raffa RB, Tallarida RJ, eds. Chemofog: cancer chemotherapy-related cognitive impairment. Austin: Springer/Landes, 147-153.
8. Macleod JE, DeLeo JA, Hickey WF, Ahles TA, Saykin AJ, Bucci DJ, (2007) Cancer chemotherapy impairs contextual but not cue specific fear memory. Behavioral Brain Research, 181, 168-172. (Pubitemid 46765012)
9. Konat GW, Kraszpulski M, James I, Zhang HT, Abraham J, (2008) Cognitive dysfunction induced by chronic administration of common cancer chemotherapeutics in rats. Metabolic Brain Disease, 23, 325-333.
10. Jansen CE, Dodd MJ, Miaskowski CA, Dowling GA, Kramer J, (2008) Preliminary results of a longitudinal study of changes in cognitive function in breast cancer patients undergoing chemotherapy with doxorubicin and cyclophosphamide. Psychooncology, 17, 1189-1195.
11. Raffa RB, Tallarida RJ, (2010) Effects on the visual system might contribute to some of the cognitive deficits of cancer chemotherapy-induced 'chemo-fog'. Journal of Clinical Pharmacy and Therapeutics, 35, 249-255.
12. Trask PC, Esper P, Riba M, Redman B, (2000) Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. Journal of Clinical Oncology, 18, 2316-2326. (Pubitemid 30350225)